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        Pulmonary surfactant homeostasis is maintained 
by the balanced production of surfactant by al-
veolar epithelium and its clearance by pulmo-
nary alveolar macrophages (  1  ). GM-CSF is a 
critical regulator of surfactant homeostasis in mice 
(  1  ). GM-CSF, via heterologous cell surface re-
ceptors comprised of      and      glycoprotein 
subunits (GM-CSF-R     and GM-CSF-R    , re-
spectively), activates STAT5 and other signal-
ing pathways (  2  ). N-linked glycosylation of the 
     subunit is required for GM-CSF binding and 
receptor signaling ( 3  ). In mice, defi  ciency of GM-
CSF (  4, 5  ) or its receptor (  6  ) impairs multiple 
functions of alveolar macrophages (  7  ), includ-
ing surfactant catabolism (  8  ), which results in pro-
gressive surfactant accumulation. 
  Pulmonary alveolar proteinosis (PAP) is a 
syndrome characterized by respiratory failure 
caused by pulmonary surfactant accumulation 
(  9, 10  ), which can be grouped into distinct cat-
egories based on clinical, histopathologic, bio-
chemical, and genetic data (  1, 9  –  12  ). Primary 
PAP occurs when GM-CSF signaling is dis-
rupted, for example in individuals with high 
levels of GM-CSF autoantibodies, which are 
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  Primary pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by accumu-
lation of surfactant in the lungs that is presumed to be mediated by disruption of granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) signaling based on studies in 
genetically modifi  ed mice. The effects of GM-CSF are mediated by heterologous receptors 
composed of GM-CSF binding (GM-CSF-R    ) and nonbinding affi  nity-enhancing (GM-CSF-
R    ) subunits. We describe PAP, failure to thrive, and increased GM-CSF levels in two sisters 
aged 6 and 8 yr with abnormalities of both GM-CSF-R      –  encoding alleles (  CSF2RA  ). One 
was a 1.6-Mb deletion in the pseudoautosomal region of one maternal X chromosome 
encompassing   CSF2RA  . The other, a point mutation in the paternal X chromosome allele 
encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine 
binding domain and glycosylation of GM-CSF-R    , severely reducing GM-CSF binding, 
receptor signaling, and GM-CSF  –  dependent functions in primary myeloid cells. Transfection 
of cloned cDNAs faithfully reproduced the signaling defect at physiological GM-CSF con-
centrations. Interestingly, at high GM-CSF concentrations similar to those observed in the 
index patient, signaling was partially rescued, thereby providing a molecular explanation 
for the slow progression of disease in these children. These results establish that GM-CSF 
signaling is critical for surfactant homeostasis in humans and demonstrate that mutations 
in   CSF2RA   cause familial PAP. 
© 2008 Suzuki et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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presumed to mediate pathogenesis by neutralizing GM-CSF 
and reducing surfactant catabolism by alveolar macrophages 
(  10, 13  ). This form, referred to as autoimmune PAP, com-
prises 90% of cases (  13  ). Primary PAP has also been associated 
with reduced detection of GM-CSF-R     on myeloid cells 
(  14, 15  ), but defi  nitive studies demonstrating heritable defi  -
ciency of either GM-CSF or its receptors as the cause of PAP 
in humans are lacking (  16  ). Secondary PAP occurs as a con-
sequence of an underlying disease presumed to impair surfactant 
clearance by reducing either the numbers or functions of al-
veolar macrophages (  9  ). Hereditary disorders of surfactant pro-
duction, for example, because of mutations in the genes encoding 
surfactant protein (SP)  –  B (  17  ), SP-C (  18  ), or ABCA3 (  19  ), 
exhibit disordered surfactant homeostasis to varying degrees 
but are distinguished from PAP by their surfactant dysfunc-
tion, disruption of alveolar wall architecture, and clinical course 
(  20  ). In this paper, we describe a family in which two chil-
dren developed primary PAP in association with loss of GM-
CSF responsiveness caused by mutations in the gene encoding 
GM-CSF-R    . 
    RESULTS AND DISCUSSION   
  Clinical presentation and phenotype 
  The index patient presented at age six with a 2-yr history of 
progressive tachypnea and failure to thrive (height and weight 
were third percentile for age [Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20080990/DC1]). Ges-
tation, delivery, birth weight (3.66 kg, 50th percentile), and 
development were all normal, but weight gain slowed by 6  –  9 
mo as did height by 2  –  3 yr. There was no history of cough, 
fever, chest pain, pneumonia or other pulmonary disease, 
environmental exposure, or drug use. Both parents were well-
developed and healthy with no history of lung disease. Ex-
amination revealed moderate tachypnea, mild tachycardia, and 
inspiratory crackles but was otherwise unremarkable. Pulmo-
nary function testing revealed severe restrictive impairment. 
Oxygen saturation was 88% while breathing room air and de-
creased while talking or walking a short distance. A diagnosis 
of PAP was suspected based on chest radiography (  Fig. 1 A  ) 
and established by histopathologic examination of lung tissue 
(  Fig. 1 B  ).   A serum GM-CSF autoantibody test (  21  ) was nega-
tive on two occasions. The patient was transferred to Cincin-
nati Children  ’  s Hospital and underwent whole lung lavage 
therapy with marked symptomatic and radiographical impro-
vement (  Fig. 1 C  ). MCP-1 and M-CSF levels in the lavage 
were increased compared with healthy controls (supplemental 
text, available at http://www.jem.org/cgi/content/full/jem
.20080990/DC1), which is similar to fi  ndings in autoimmune 
PAP patients and GM-CSF KO mice (  22, 23  ). 
  An inherited defect in GM-CSF receptor function was 
suspected based on the constellation of histopathology show-
ing well-preserved alveolar wall architecture (  Fig. 1 B  ), the 
absence of GM-CSF autoantibodies (  21  ), and an abnormal 
CD11b stimulation index test (  24  ). Therefore, all immediate 
family members were evaluated. Because SP is in serum in 
PAP and levels refl  ect lung disease severity (  25  ), serum SP-D 
    Figure 1.         Phenotypic characterization of patients with familial 
PAP.   (A) Chest radiograph (top) and high-resolution computed tomogram 
of the chest (bottom) of the index patient at presentation. (B) Histopatho-
logic appearance of the open lung biopsy from the index patient after 
staining with hematoxylin and eosin (H  &  E) or immunostaining for SP-A, 
mature SP-B, Pro  –  SP-C, SP-D, and ABCA3. Note the lymphocytosis in the 
low-power hematoxylin and eosin  –  stained section and the intact alveolar 
wall in the high-powered hematoxylin and eosin  –  stained section. Images 
were obtained at a total magnifi  cation of 50  ×   (top) or 400  ×   (all others). 
Bars: (top) 100   μ  m; (all others) 10   μ  m. (C) Chest radiograph of the index 
patient 4 mo after presentation immediately before (top) and 5 d after 
(bottom) whole lung lavage therapy. (D) Serum SP-D levels in affected 
siblings, parents, and a control. The mean   ±   SD serum SP-D concentration 
in 67 healthy controls was 63.5   ±   39 ng/ml (hatched region) and in 12 
patients with autoimmune PAP was 174   ±   83 ng/ml (not indicated). 
(E) High-resolution computed tomogram showing diffuse patchy ground 
glass opacities representing mild PAP in the affected sister.     JEM VOL. 205, November 24, 2008  2705
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ter with predominantly lower molecular mass forms compared 
with the control (  Fig. 2 B  ). The father was heterozygous for 
normal and lower molecular mass forms. Unexpectedly, 
the mother exhibited only a normal pattern. To evaluate cell-
mediated clearance of GM-CSF, blood mononuclear cells 
from the patient (  Fig. 2 C  ) and her sister (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20080990/DC1) 
were incubated with GM-CSF, and both failed to clear GM-
CSF in contrast to control and parental leukocytes. The con-
centration of GM-CSF in lung lavage was markedly increased 
in the patient compared with healthy controls, in whom it 
was undetectable (  Fig. 2 D  ). The in vivo concentration of 
pulmonary GM-CSF in the epithelial lining fl  uid of the lungs 
was estimated to be 6.9 and 27 ng/ml (right and left lungs, 
respectively) using the urea dilution method (  26  ). Pulmonary 
was measured and found to be increased in the patient com-
pared with her parents and controls (  Fig. 1 D  ). Unexpect-
edly, the patient  ’  s 8-yr-old sister, who was previously thought 
to be healthy, had increased serum SP-D. Subsequent clinical 
evaluation revealed that the sister had poor growth (height 
and weight, 10th percentile for age; Fig. S1B), a diff  usion 
  capacity for carbon dioxide of 57% that predicted, and mild 
patchy ground glass opacities throughout both lungs, which 
are consistent with a diagnosis of PAP (  Fig. 1 E  ). 
  Structure and function of the GM-CSF receptor 
  Flow cytometry indicated that GM-CSF-R     and GM-CSF-
R     were present on blood leukocytes in all family members 
(  Fig. 2 A  ).   Western blotting revealed an abnormal electro-
phoretic pattern for GM-CSF-R     in the patient and her sis-
    Figure 2.         Structural and functional analysis of GM-CSF receptor defects.   (A) Flow cytometry demonstrating GM-CSF-R     and  GM-CSF-R    on 
the cell surface of peripheral blood leukocytes in all family members. (B) Western blots of PBMC lysates using antibodies to detect GM-CSF-R     or 
actin as indicated. (C) GM-CSF clearance assay. Blood leukocytes from the patient were unable to remove exogenous GM-CSF added to culture 
medium at time zero in contrast to leukocytes from two controls that rapidly bound and cleared GM-CSF. Error bars show the means   ±   SE. 
(D and E) Measurement of GM-CSF concentration by ELISA. GM-CSF was readily detected in lavage from the patient but was not detected (ND) in 
lung lavage from nine healthy controls (D). GM-CSF was detected in the serum of affected siblings but not their parents or a control (E). (F) Blood 
leukocytes   isolated from the indicated family members were incubated for 15 min in the absence (    ) or presence (+) of 10 ng/ml GM-CSF, followed 
by Western blotting of cell lysates to detect total STAT5 (STAT5), phosphorylated STAT5 (pSTAT5), or actin. (G) Measurement of the GM-CSF  –  stimulated 
increase in CD11b levels on leukocytes in whole blood. The CD11b stimulation index (  24  ) was calculated as the mean fl  uorescence of CD11b on leuko-
cytes incubated with GM-CSF minus that of unstimulated cells divided by that of unstimulated cells and multiplied by 100. (H) Similar to F except that 
a higher GM-CSF concentration (1,000 ng/ml) was used and cell lysates were immunoprecipitated with anti-STAT5 antibody before Western blotting 
to detect total STAT5 (STAT5) or phosphorylated STAT5 (pSTAT5).     2706   CSF2RA   MUTATIONS AND FAMILIAL PULMONARY ALVEOLAR PROTEINOSIS   | Suzuki et al. 
    Figure 3.         Genetic analysis of   CSF2RA   gene defects.   (A) Nucleotide sequence of   CSF2RA   in genomic DNA from each family member, including nt 
580  –  591 of the coding sequence (numbered relative to the initiation codon; from GenBank/EMBL/DDBJ under accession no.   NM_006140.3  ). The index 
patient and her sister exhibited only a G  →  A point mutation at nt 586. The father was heterozygous for this substitution and the mother exhibited only 
the normal sequence. (B) FISH analysis to detect   CSF2RA   sequences in genomic DNA from the father and the patient. The probe (CTD-3047L21), which 
maps to the pseudoautosomal region (Xp22.33 and Yp11.32), hybridized to both X and Y chromosomes in the father (white arrows) and to one (white 
arrow), but not the other (yellow arrow), X chromosome in the patient. 8  –  10 metaphase cells and 25 interphase cells were evaluated for each individual. 
Similar FISH analyses are shown for each family member in the supplemental material (available at http://www.jem.org/cgi/content/full/jem.20080990/DC1). 
Images were obtained at a total magnifi  cation of 1000  ×  . (C) CGH analysis for the patient in the region of Xp22.33. The relative fl  uorescence of fl  uores-
cently labeled DNA from the patient (open circles) compared with a same-sex reference DNA (fi  lled circles) after hybridization to various BAC clones on 
the SignatureSelect V2 chip representing the Xp22.33 region is shown. Reduced hybridization to several BAC clones (clones B and C) is indicated by the 
lower fl  uorescence of the patient  ’  s DNA compared with the reference DNA for these BAC clones. The telomeric breakpoint is mapped to between clones A 
and B and the centromeric breakpoint is mapped to between clones C and D. These data indicate an interstitial deletion of     1.264 Mb at Xp22.33 encom-
passing     1,610,183  –  2,873,864 bp. The dashed line represents a relative fl  uorescence of zero. (D) High-resolution SNP mapping of the Xp22 region for 
paternal and maternal X chromosomes. A schematic shows the locations of the point mutation (  CSF2RA  G174R  ) in the paternal X chromosome and the 
1.6-Mb deletion at Xp22.33 in the maternal X chromosome and the genes encompassed. The base 2 ratio of normalized hybridization intensities for pa-
tient and reference samples (log R ratio) is shown. Similar SNP analyses for each family member are shown in the supplemental material (available at 
http://www.jem.org/cgi/content/full/jem.20080990/DC1). (E) Map showing a portion of the X chromosome summarizing the genetic analysis used to iden-
tify the small maternal X chromosomal deletion at Xp22.33 encompassing   CSF2RA  . The probe used for FISH analysis (hatched bar) is the same as clone B 
on the CGH microarray chip. The locations of selected CGH microarray probes in the region of the CSF2RA gene are shown. Those CGH probes showing JEM VOL. 205, November 24, 2008  2707
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of   CSF2RB   was similar in all family members and a control 
(Fig. S4). Routine cytogenetic analysis was normal in all fam-
ily members (Fig. S5), ruling out a large chromosomal abnor-
mality. Fluorescent in situ hybridization (FISH) demonstrated 
a deletion in the pseudoautosomal region 1 of the X chromo-
some in the patient (  Fig. 3 B  ), her sister, and mother (Fig. S6) 
that was not present in the father (  Fig. 3 B  ). Further evaluation 
using comparative genomic hybridization (CGH) demon-
strated an interstitial deletion encompassing the region from 
    1,610,183 to 2,873,864 bp on one maternal-derived X chro-
mosome in the patient (  Fig. 3 C  ), her sister, and mother (not 
depicted). High-resolution single-nucleotide polymorphism 
(SNP) mapping further defi  ned this small deletion as extend-
ing from 1,308,324 to 2,881,011 bp in one maternal X chro-
mosome (  Fig. 3 D  ) and in both siblings (Fig. S7). Importantly, 
this deletion encompassed the  CSF2RA   allele ( Fig. 3 E ), thereby 
explaining the unexpected   CSF2RA   DNA and mRNA se-
quence results. 
  These results demonstrate the inheritance of compound het-
erozygous abnormalities of   CSF2RA   in both siblings (  Fig. 3 F  ). 
The G174R mutation present on the paternal X chromosome, 
localized to the extracellular cytokine binding domain of GM-
CSF-R    , alters a potential site of glycosylation and impairs 
GM-CSF binding and receptor signaling. However, it is un-
clear if the functional impairment is caused by the change in 
primary amino acid sequence or loss of glycosylation. 
  Reproduction of the   CSF2RA    G174R   abnormality 
  To reproduce the GM-CSF receptor signaling defect identi-
fi  ed in this family, plasmids expressing   CSF2RB   and either 
  CSF2RA    G174R   or   CSF2RA    WT   were cotransfected into 293 cells. 
Western blotting showed receptor proteins of the expected 
size from   CSF2RA    WT   and smaller molecular forms from 
  CSF2RA    G174R   (  Fig. 4 A  ), which is similar to results for pri-
mary leukocytes (  Fig. 2 B  ).   Treatment of transduced cell ly-
sates with Peptide: N-Glycosidase F, an amidase that cleaves 
between the innermost GlcNAc and asparagine residues of 
high mannose oligosaccharides ( 3  ), resulted in a similar electro-
phoretic pattern for normal and G174R GM-CSF-R    . This 
confi  rmed the G174R mutation alters N-linked glycosyl-
ation (  Fig. 4 A  ) by disrupting a functional N-linked glycosyl-
ation site and that glycosylation is responsible for the smaller 
molecular forms from this allele. GM-CSF-R     was expressed in 
  CSF2RB  -transfected cells but was undetectable in nontrans-
fected cells (unpublished data). GM-CSF binding studies dem-
onstrated that cells expressing  CSF2RA    WT   and  CSF2RB   rapidly 
bound GM-CSF and removed it from the media, whereas cells 
expressing   CSF2RA    G174R   and   CSF2RB   or   CSF2RB   alone 
balanced hybridization to patient and control DNA are shown as clear boxes (A and D), whereas those showing an unbalanced hybridization representing 
sequences deleted in the patient are shown in black. High-resolution SNP analysis revealed that the deletion (red bar) extended from 1,308,324 to 
2,881,011 bp. Sequence analysis (A) and PCR quantifi  cation of   CSF2RA   exon 7 (Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20080990/DC1) 
demonstrated that the deletion included   CSF2RA   exon 7. The chromosomal location of the   CSF2RA   gene (1,347,701  –  1,388,827 bp) is indicated. (F) Pedigree of the 
family deduced from sequencing and   CSF2RA   allelic copy number determination experiments. The index case is indicated (arrow).     
 
GM-CSF was also increased in  CSF2RB  -defi  cient mice (Fig. S3), 
confi  rming the relationship between GM-CSF receptor dys-
function and increased pulmonary GM-CSF levels. Serum 
GM-CSF was increased in both aff  ected siblings and unde-
tectable in both parents and control, indicating that the ab-
normality was systemic (  Fig. 2 E  ). GM-CSF receptor function 
was impaired in both aff  ected siblings, as shown by reduced 
GM-CSF  –  stimulated phosphorylation of STAT5 (  Fig. 2 F  ) 
and failure of GM-CSF to increase CD11b levels on leuko-
cytes from the patient compared with controls (  Fig. 2 G  ). 
  The slower-than-expected rate of progression of PAP 
in both aff  ected siblings led us to hypothesize that the GM-
CSF-R     abnormality may not completely abolish GM-CSF 
signaling. This was confi  rmed by incubation of primary blood 
mononuclear cells with a higher concentration of GM-CSF 
(1,000 ng/ml), which resulted in partial receptor signaling as 
shown by an increase in phosphorylated STAT5 (  Fig. 2 H  ). 
Thus, although both GM-CSF-R     and      chains were present 
on leukocytes in all family members, in the two aff  ected sib-
lings, the GM-CSF-R     chain was structurally abnormal, which 
severely reduced but did not completely abolish GM-CSF bind-
ing and GM-CSF  –  dependent signaling and cellular functions. 
  Genetic analysis of the GM-CSF receptor 
  The nucleotide sequence of the   CSF2RA   gene in genomic 
DNA from both siblings revealed a single G  →  A point mutation 
in exon 7 that encoded a nonconservative amino acid change 
(glycine to arginine) at position 174, G174R (  Fig. 3 A  ).   This 
change alters one of the 11 potential sites of N-glycosylation, 
which is required for GM-CSF receptor function (  3, 27  ). The 
father was heterozygous for mutant   CSF2RA    G174R   and WT 
(  CSF2RA    WT  ) alleles (  Fig. 3 A  ), whereas only the   CSF2RA    WT   
sequence was detected in the mother (  Fig. 3 A  ). The sequence 
of   CSF2RA   in leukocyte messenger RNA (mRNA) was simi-
lar to the respective DNA sequence for each family member, 
even when cDNA was overamplifi  ed to detect potentially un-
derrepresented mRNA sequences (unpublished data). This ab-
sence of a normal sequence for   CSF2RA   exon 7 in both siblings 
and the absence of the point mutation in the mother suggested 
that one maternal   CSF2RA   allele may be deleted in the pa-
tient, her sister, and their mother. The nucleotide sequence of 
  CSF2RB   in leukocyte mRNA from all family members was 
normal (unpublished data). 
  PCR amplifi  cation demonstrated a reduced copy num-
ber of   CSF2RA   in genomic DNA from both siblings and 
their mother compared with the father and a healthy control 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20080990/DC1). In contrast, the genomic copy number 2708   CSF2RA   MUTATIONS AND FAMILIAL PULMONARY ALVEOLAR PROTEINOSIS   | Suzuki et al. 
tion of   CSF2RA    G174R  /  CSF2RB  -transduced cells with higher 
concentrations of GM-CSF in the range of those observed in the 
index patient gave results similar to those obtained with primary 
leukocytes and clearly demonstrated a modest dose-  dependent 
increase in STAT5 phosphorylation, which is consistent with a 
partial rescue of the signaling abnormality (  Fig. 4 D  ). 
  Clinical relevance of the   CSF2RA    G174R   mutation 
  Our fi  ndings demonstrate that familial primary PAP in hu-
mans is caused by compound heterozygous abnormalities of 
  CSF2RA  , including loss of heterozygosity and a function-al-
tering point mutation that severely reduces GM-CSF recep-
tor signaling. These are the fi  rst results to demonstrate familial 
primary PAP in humans and that GM-CSF-R     is critical for 
surfactant homeostasis. They extend previous fi  ndings that 
PAP is caused by the absence of GM-CSF or GM-CSF-R     
in mice (  4  –  6  ) or is specifi  cally associated with the presence of 
neutralizing GM-CSF autoantibodies or a reduction in alve-
olar macrophage numbers or function in humans (  9, 10  ). The 
allelic frequency of these mutations has not been determined 
but may be rare given that autoantibodies against GM-CSF 
account for most individuals with PAP. 
  Both aff  ected siblings had impaired pulmonary function 
and failure to thrive, supporting the conclusion that prolonged 
respiratory insuffi   ciency in children retards growth. Impor-
tant to this conclusion is the observation that Xp22.33 dele-
tion did not include the   SHOX   (  short stature homeobox  ) gene, 
the deletion of which impairs growth (  28  ). Further, hetero-
zygous loss of   CSF2RA   in the mother did not impair growth. 
Early results suggest that whole lung lavage therapy was followed 
by an increase in growth acceleration in the index patient. 
  This study highlights the usefulness of several novel bio-
markers in the diagnostic evaluation of PAP. The combination 
of a negative GM-CSF autoantibody test (  29  ) and an abnormal 
CD11b stimulation index (  24  ) predicted the GM-CSF recep-
tor dysfunction, which was confi  rmed by the lack of GM-CSF 
binding and defective GM-CSF receptor signaling. GM-CSF 
levels were increased in lung lavage from the patient and, in 
serum from the patient and her sister, compared with family 
members and healthy controls. Because primary PAP is pre-
sumed to be caused by a defect in GM-CSF regulation of 
  alveolar macrophage surfactant catabolism (  9, 10  ), an elevated 
serum GM-CSF level may be useful as a biomarker to distin-
guish primary PAP caused by GM-CSF autoantibodies (90% 
of all cases of PAP) (  9, 10, 13, 30  ) from PAP caused by GM-
CSF receptor dysfunction (this study; references   14  –  16  ) and 
PAP caused by GM-CSF defi  ciency (  4, 5  ) (not yet reported in 
humans). Finally, an increased serum SP-D level predicted the 
occurrence of PAP in the sister, which was confi  rmed by sub-
sequent clinical and radiographical evaluation. 
  The slow progression and diff  erences in severity of the 
lung disease between aff  ected siblings with the same   CSF2RA   
mutations and GM-CSF-R     dysfunction indicates that pene-
trance is important in familial PAP because of GM-CSF recep-
tor defects. The increased levels of GM-CSF likely refl  ect 
im  paired clearance but are also consistent with interruption of a 
did not clear GM-CSF (  Fig. 4 B  ). Cotransfection of   CSF2RB   
together with   CSF2RA    WT  , but not with   CSF2RA    G174R  , 
resulted in expression of functional GM-CSF receptors as 
demonstrated by GM-CSF  –  dependent phosphorylation of 
STAT5 only with the former combination (  Fig. 4 C  ). Incuba-
    Figure 4.         Reproduction of the   CSF2RA    G174R   gene defect.   (A)  West-
ern blots of nontransfected 293 cell lysates (control) or lysates of cells 
transfected with plasmids expressing   CSF2RB   and either   CSF2RA  WT   (WT)  or 
  CSF2RA  G174R   (G174R), followed by incubation with (+) or without (   ) 
Peptide: N-Glycosidase F (PNGase F) and detection with antibodies 
against GM-CSF-R     or actin. (B) Evaluation of cell-mediated binding and 
removal of exogenous GM-CSF from the culture media. Asterisks indicate 
signifi  cant differences in levels of GM-CSF in media from cells expressing 
  CSF2RA  WT / CSF2RB   compared with cells expressing   CSF2RA  G174R / CSF2RB , 
  CSF2RB   alone or media without cells. Error bars show the means   ±   SE. 
(C) Evaluation of GM-CSF  –  stimulated phosphorylation of STAT5 in 293 
cells transfected as described in A and incubated for 15 min in the ab-
sence (    ) or presence (+) of 10 ng/ml GM-CSF. Lysates were evaluated by 
Western blotting (WB) to detect total STAT5 (STAT5) or were immuno-
precipitated with anti-STAT5 antibody and then evaluated by Western 
blotting (IP + WB) to detect total STAT5 or phosphorylated STAT5 (pSTAT5). 
(D) Similar to C, except that increased concentrations of GM-CSF were 
used for evaluate GM-CSF receptor function.     JEM VOL. 205, November 24, 2008  2709
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with published sequences (from GenBank/EMBL/DDBJ under acces-
sion nos.   NM_006140.3   and   BC070085  , respectively). The relative copy 
number of   CSF2RA   and   CSF2RB   genes among family members and 
a healthy control was measured by amplifi  cation of genomic DNA using 
PCR with gene-specifi  c oligonucleotides followed by analysis of products 
by electrophoresis on 2% agarose gels. Experimental methods for measur-
ing gene copy number, evaluating the genes encoding SP-B, SP-C, and 
ABCA3 (  19, 31  ) for function-altering mutations, cytogenetic analysis, CGH 
analysis, FISH, and high-resolution SNP array analysis (  32  ) are described 
in the supplemental Materials and methods (available at http://www.jem
.org/cgi/content/full/jem.20080990/DC1). 
  Reproduction of the GM-CSF receptor defect.     The methods used to 
clone and express mRNA transcripts encoding GM-CSF-R     and      chains 
in cultured cells and evaluate protein glycosylation are described in the sup-
plemental Materials and methods. 
  Statistical analysis.     Numeric data are presented as means   ±   SE. Statistical 
comparisons were made with Student  ’  s   t   test for two-group comparisons and 
with one-way analysis of variance with posthoc analysis according to the 
Holm-Sidak method for multiple-group comparisons. P-values of   <  0.05 
were considered to indicate statistical signifi  cance. 
  Online supplemental material.     Fig. S1 shows normalized growth curves 
for the index patient and her sister. Fig. S2 shows GM-CSF binding and 
clearance by blood leukocytes from aff  ected and unaff  ected family members 
and control. Fig. S3 shows increased pulmonary GM-CSF levels in GM-
CSF receptor      chain (  Csf2rb  ) KO mice. Fig. S4 shows evaluation of   CS-
F2RA   and CSF2FB gene copy number by PCR amplifi  cation. Fig. S5 shows 
karyotypes of high-resolution GTG-banded chromosomes. Fig. S6 shows eval-
uation of heterozygosity at the   CSF2RA   locus by FISH. Fig. S7 shows high-
resolution SNP analysis. The supplemental text contains additional details 
regarding the case histories and clinical laboratory and other data cited 
throughout the text. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20080990/DC1. 
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